Holen Sie sich die Stockscreener-App
0.3553
1.02%
-0.0084
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture (SCNX) CFO shows no personal stake in company stock - Stock Titan
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Scienture Holdings Q2 Results: EPS beats estimate, sales miss - scanx.trade
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Scienture Holdings Inc (SCNX) Stock News Today - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 64.35%New Analyst Coverage - vinanet.vn
Scienture Holdings (SCNX) Holds Near $0.38 as Trading Range Tightens Between $0.36 Support and $0.40 ResistanceComposite Profile - dars.gov.et
Scienture Holdings, Inc. (NASDAQ: SCNX) Stock Price, News & Analysis - Kalkine
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, But Shares Slide 4%Guidance Upgrade Report - vinanet.vn
Scienture Holdings, Inc. Revenue Breakdown – NASDAQ:SCNX - TradingView
Scienture Holdings Inc (SCNX) Cash Flow - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable? - simplywall.st
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBITDA forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Strong EPS SurpriseAnalyst Earnings Estimate - vinanet.vn
Scienture Holdings Inc (SCNX) Balance Sheet - TradingKey
Scienture Holdings Inc (SCNX) Income Statement - TradingKey
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SCNX|Scienture Holdings Inc|Price:0.370|Chg%:+0.001 - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SCNX|Scienture Holdings Inc|Price:0.372|Chg%:+0.003 - TradingKey
SCNX|Scienture Holdings Inc|Price:0.357|Chg%:-0.012 - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings (SCNX) Faces Modest Decline, Testing Key Support at $0.37Dark Pool Sentiment - vinanet.vn
DataMEDS AI Intends to Target GLP-1 Muscle Loss and Long COVID - Stock Titan
SCNX SEC FilingsScienture Holdings, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Scienture completes manufacturing for naloxone spray launch By Investing.com - Investing.com Nigeria
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionConsensus Beat Rate - dars.gov.et
$Scienture Holdings (SCNX.US)$ - Moomoo
Scienture Holdings stock jumps over 20% pre-market: Here's why - MSN
Scienture Holdings Company Profile & Introduction - Moomoo
Scienture Holdings (SCNX) Surges Over 11%: Key Levels to WatchLow Volatility Picks - dars.gov.et
Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX) - The Globe and Mail
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why - Sahm
Scienture Holdings (SCNX) Registration filing Summary - Quartr
4.35%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):